1 min read
MaxCyte Preliminary Q3 Core Revenue Rises 26% to About $8.1 Million
The preliminary figure covers MaxCyte’s core business for the third quarter of 2026.

MaxCyte’s preliminary core business revenue rose 26% year over year to about $8.1 million in the third quarter of 2026.
The revenue figure is preliminary and covers MaxCyte’s core business.